{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:24:00Z","timestamp":1778682240691,"version":"3.51.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1097\/bor.0000000000000235","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T16:33:24Z","timestamp":1448382804000},"page":"15-20","source":"Crossref","is-referenced-by-count":11,"title":["B-cell-targeted therapy in systemic vasculitis"],"prefix":"10.1097","volume":"28","author":[{"given":"Lindsay","family":"Lally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis.","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"1992. Wegener granulomatosis: an analysis of 158 patients.","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide.","volume":"128","author":"Cupps","year":"1982","journal-title":"J Immunol"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrrheum.2010.158","article-title":"ANCA-associated vasculitides - advances in pathogenesis and treatment.","volume":"6","author":"Chen","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis.","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis.","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomized trial.","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheum"},{"key":"R12-5-20210128","first-page":"333","article-title":"Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFFAPRIL targeting agents.","volume":"9","author":"Lenert","year":"2015","journal-title":"Drug Des DevelTher"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis: comparison of efficacy in granulomatous versus vasculitic manifestation.","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegeners granulomatosis with refractory granulomatous manifestations.","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R15-5-20210128","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegeners with refractory granulomatous manifestations.","volume":"35","author":"Seo","year":"2008","journal-title":"J Rheum"},{"key":"R16-5-20210128","first-page":"328","article-title":"B-cell depletion with rituximab for refractory head and neck Wegeners granulomatosis: a cohort study.","volume":"34","author":"Martinez","year":"2009","journal-title":"ClinOtolaryngol"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/acr.22311","article-title":"Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (Wegeners).","volume":"66","author":"Lally","year":"2014","journal-title":"Arthritis Care Res"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegeners): a single-center ten-year experience.","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegeners). Results of a single-center cohort study on 66 patients.","volume":"50","author":"Calich","year":"2014","journal-title":"J Autoimmun"},{"key":"R22-5-20210128","first-page":"abtstract","article-title":"Rituximab versus azathioprine for maintenance in antineutrophile cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): follow-up at 34 months.","volume":"42","author":"Terier","year":"2013","journal-title":"La PresseMedicale"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-assoicatedhypogammaglobulinemia: incidence, predictors and outcomes in patients with multisystemi autoimmune disease.","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R31-5-20210128","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","article-title":"Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R32-5-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/ard.2011.153007","article-title":"Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.","volume":"71","author":"Hoyer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R34-5-20210128","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10067-014-2506-5","article-title":"Two Takayasu arteritis patients successfully treated with rituximab.","volume":"33","author":"Caltran","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R35-5-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/BOR.0000000000000004","article-title":"Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies.","volume":"26","author":"Clifford","year":"2014","journal-title":"Curr Opin Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T23:29:00Z","timestamp":1692142140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201601000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000235","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}